ロード中...
New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base
Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (E...
保存先:
| 出版年: | Epidemiol Psychiatr Sci |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cambridge University Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6998643/ https://ncbi.nlm.nih.gov/pubmed/28004623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S2045796016001025 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|